刺激性咳嗽症候群治療市場－全球產業規模、佔有率、趨勢、機會及預測（依藥物類別、通路、地區及競爭格局分類，2021-2031年）

全球咳嗽刺激症候群治療市場預計將從 2025 年的 45.4 億美元成長到 2031 年的 63.4 億美元，複合年成長率為 5.72%。

咳嗽過敏症候群 (CHS) 是一種臨床疾病，其特徵是由於感覺神經過敏，導致低強度化學、熱或機械刺激誘發慢性咳嗽，且即使在原發性疾病得到治療後，咳嗽症狀也常常持續存在。人口老化和呼吸系統疾病盛行率的上升是推動該市場成長要素，這使得人們迫切需要有效治療現有鎮咳藥物無法解決的難治性病例。龐大的患者群也支撐著這龐大的市場需求。根據歐洲呼吸學會 (ERS) 2024 年發布的報告，慢性咳嗽影響著全球約 5-10% 的成年人，這表明新型神經調節藥物存在巨大的未滿足需求。

然而，新興治療方法的安全性問題引發了嚴格的監管壁壘，嚴重阻礙了市場擴張。由於擔心味覺障礙等副作用，衛生監管機構對新藥候選產品，特別是P2X3拮抗劑，制定了嚴格的標準。這種嚴格的審查需要大量的臨床檢驗，導致關鍵地區的產品核可延遲，並成為新治療方法快速商業化和全球整個行業發展的主要障礙。

市場促進因素

新型P2X3受體拮抗劑的問世是推動全球咳嗽過敏症候群治療市場變革的重要催化劑。這些藥物針對氣道感覺神經元上的P2X3受體，阻斷驅動高敏感性咳嗽反射的ATP訊號路徑。與傳統的神經抑制劑相比，此藥物的作用機轉更為特異性，後者主要針對神經元敏化的生理根源。這些候選藥物臨床療效的證實正在提振市場信心。例如，2025年3月發表於《美國呼吸與危重症醫學雜誌》的報告顯示，P2X3拮抗劑camripixant的IIb期研究顯示，在安慰劑校正的以金額為準上，24小時咳嗽頻率降低了34%。這種標靶定向是關鍵促進因素，可望為此前缺乏有效治療方案的患者帶來更好的治療效果。

同時，針對多種神經系統標靶的強大臨床研發管線以及不斷成長的藥物研發投入正在推動市場發展。為了應對疾病的異質性，各公司正在探索P2X3受體抑制以外的機制，例如鴉片受體促效劑。根據FirstWord Pharma於2025年3月報道，在IIa期RIVER試驗中，試驗性藥物Hadubio在校正安慰劑後，使咳嗽頻率顯著降低了57%。鑑於患者負擔沉重，這種積極的創新至關重要。 2025年7月發表於ERJ Open Research的一項研究表明，高達27.9%的慢性咳嗽患者可能患有難治性或不明原因的慢性咳嗽，這凸顯了該行業向精準醫療的重大轉變。

市場挑戰

全球咳嗽過敏症候群治療市場的成長受到新治療方法安全性方面嚴格監管障礙的顯著限制。由於有通報某些藥物有味覺障礙等不良反應風險，衛生監管機構對新藥候選藥物，尤其是涉及P2X3受體拮抗劑的藥物，制定了嚴格的標準。這種嚴格的審查需要廣泛的臨床檢驗，導致研發週期延長，產品核可嚴重滯後，直接阻礙了新治療方法的快速商業化。

這些監管瓶頸嚴重阻礙了滿足對標準治療無效患者的需求，限制了市場參與企業的收入潛力。大量難治性病例因延誤而未能解決，凸顯了錯失良機的巨大影響。歐洲呼吸學會 (ERS) 2024 年的一項調查發現，在評估族群中，高達 27.9% 的慢性咳嗽患者被歸類為潛在難治性或病因不明的慢性咳嗽。因此，無法迅速通過這些安全法規的核准，導致重要的神經調節藥物上市延遲，從而有效地限制了全球市場的擴張。

市場趨勢

人工智慧驅動的聲學咳嗽監測技術的整合，從根本上改變了過敏性咳嗽症候群的治療管理方式，將診斷和治療追蹤從患者主觀記憶轉變為客觀、連續的數據分析。這項技術不僅提高了診斷準確性，還能夠提供直接針對疾病行為因素的數位療法。這些平台的臨床效用正日益凸顯。 2025年10月，Hyfe公司發表了一項重要研究成果，顯示數位行為咳嗽抑制療法可使病因不明的難治性慢性咳嗽患者的平均咳嗽頻率降低41.8%。這些進展凸顯了市場趨勢，即醫療軟體（SaMD）在藥物治療中發揮著不可或缺的補充作用，提供非侵入性措施來改善患者的生活品質。

同時，為應對慢性咳嗽病理的異質性，慢性咳嗽專科診所的建立正在加速推進。這些診所促進了包括物理治療、語言治療和精準表現型分析在內的跨學科診療模式。這些專科中心對於對標準止咳治療無效的患者進行分層，以及透過系統化的註冊登記系統產生大規模的真實世界證據至關重要。這項基礎設施的擴展體現在多項重要的泛歐措施。正如2025年9月《歐洲呼吸雜誌開放研究》所詳述的，NEuroCOUGH慢性咳嗽註冊登記計畫啟動，該計畫在歐洲13個中心招募了2500名患者，旨在規範專科診療並改善新興治療方法的臨床試驗基礎設施。這一趨勢標誌著治療路徑正朝著更差異化和嚴謹的方向發展，確保新型治療方法應用於最合適的患者群體。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球易激惹咳嗽症候群治療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依藥物類別（鎮咳藥、吸入性皮質類固醇、短效BETA2促效劑、抗膽鹼能藥物、抗組織胺、質子幫浦阻斷劑、其他）
  • 通路（醫院藥房、零售藥房、網路藥房）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美易激惹咳嗽症候群治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲易激惹咳嗽症候群治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區易激惹咳嗽症候群治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲過敏性咳嗽症候群治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲易激惹咳嗽症候群治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球易激惹咳嗽症候群治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Pfizer Inc.
• GlaxoSmithKline plc.
• Boehringer Ingelheim GmbH.
• AstraZeneca PLC.
• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Novartis AG.
• Merck & Co. Inc.
• Vertex Pharmaceuticals Incorporated.
• Johnson & Johnson Consumer Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Cough Hypersensitivity Syndrome Treatment Market is projected to grow from USD 4.54 Billion in 2025 to USD 6.34 Billion by 2031, expanding at a CAGR of 5.72%. Cough Hypersensitivity Syndrome (CHS) is characterized as a clinical condition where chronic coughing is triggered by low-level chemical, thermal, or mechanical stimuli due to sensory neuronal hypersensitivity, often persisting even after underlying comorbidities are treated. The market is primarily driven by an aging population and the increasing prevalence of respiratory disorders, which create a need for effective management of refractory cases that existing antitussives cannot resolve. This significant demand is supported by the scale of the affected demographic; the European Respiratory Society reported in 2024 that chronic cough affects approximately 5% to 10% of adults worldwide, indicating a substantial unmet medical need for new neuromodulators.

However, market expansion faces significant impediments due to stringent regulatory hurdles related to the safety profiles of emerging therapies. Health authorities have established rigorous standards for novel candidates, particularly P2X3 antagonists, because of concerns regarding adverse effects like taste disturbances. This intense scrutiny requires extensive clinical validation and has caused delays in product approvals within key regions, acting as a major barrier to the rapid commercialization of new treatments and the overall growth of the global sector.

Market Driver

The introduction of novel P2X3 receptor antagonists is a primary catalyst transforming the Global Cough Hypersensitivity Syndrome Treatment Market. These agents target P2X3 receptors on airway sensory neurons to block the ATP signaling pathway that drives the hypersensitive cough reflex, offering a highly specific mechanism compared to traditional central nervous system suppressants that addresses the physiological root of neuronal sensitization. Market confidence is being accelerated by the clinical validation of these candidates; for example, the American Journal of Respiratory and Critical Care Medicine reported in March 2025 that Phase IIb results for the P2X3 antagonist camlipixant showed a 34% placebo-adjusted reduction in 24-hour cough frequency. This targeted efficacy is a pivotal driver, promising better outcomes for patients who historically have had no effective options.

Concurrently, the market is propelled by a strong clinical pipeline and increasing pharmaceutical R&D investment focused on diverse neurological targets. To address the heterogeneous nature of the condition, companies are exploring mechanisms beyond P2X3 inhibition, such as opioid receptor agonists. As noted by FirstWord Pharma in March 2025, the investigational therapy Haduvio achieved a statistically significant 57% placebo-adjusted reduction in cough frequency in the Phase IIa RIVER trial. This aggressive innovation is crucial given the substantial patient burden; a July 2025 study in ERJ Open Research identified that up to 27.9% of the chronic cough population suffers from possible refractory or unexplained chronic cough, underscoring a major industry shift toward precision medicine.

Market Challenge

The growth of the Global Cough Hypersensitivity Syndrome Treatment Market is significantly restricted by stringent regulatory hurdles concerning the safety profiles of emerging therapies. Health authorities have mandated rigorous standards for novel candidates, especially P2X3 antagonists, due to documented risks of adverse effects such as taste disturbances. This intense scrutiny necessitates extensive clinical validation, leading to prolonged development timelines and substantial delays in product approvals, which directly hinders the rapid commercialization of new treatments.

These regulatory bottlenecks create a critical barrier to meeting the needs of patients who do not respond to standard care, thereby limiting the revenue potential for market participants. The magnitude of this missed opportunity is underscored by the prevalence of difficult-to-treat cases that remain unaddressed due to these delays. According to the European Respiratory Society in 2024, research indicated that up to 27.9% of individuals with chronic cough in assessed populations were classified as having possible refractory or unexplained chronic cough. Consequently, the inability to swiftly navigate these safety regulations stalls the introduction of vital neuromodulators, effectively capping the expansion of the global sector.

Market Trends

The integration of AI-driven acoustic cough monitoring is fundamentally reshaping the management of Cough Hypersensitivity Syndrome by shifting diagnosis and treatment efficacy tracking from subjective patient recall to objective, continuous data analysis. This technology not only improves diagnostic precision but also enables the delivery of digital therapeutics that directly address the behavioral components of the condition. The clinical utility of these platforms is becoming increasingly clear; in October 2025, Hyfe, Inc. reported that a pivotal study showed digital Behavioral Cough Suppression Therapy reduced average cough frequency by 41.8% in patients with refractory and unexplained chronic cough. Such advancements highlight a market trend where software-as-a-medical-device (SaMD) acts as an integral companion to pharmacological interventions, offering a non-invasive method to enhance patient quality of life.

Simultaneously, the establishment of specialized chronic cough clinics is gaining momentum as a structural response to the disease's heterogeneity, facilitating multidisciplinary care models that include physiotherapy, speech therapy, and precise phenotyping. These dedicated centers are essential for stratifying patients who fail standard antitussive therapy and for fostering large-scale real-world evidence generation through organized registries. This infrastructural expansion is exemplified by major pan-European initiatives; as detailed in the European Respiratory Journal Open Research in September 2025, the NEuroCOUGH Chronic Cough Registry was launched to recruit 2,500 patients across 13 European sites to standardize specialist care and improve the clinical trial infrastructure for emerging therapies. This trend signifies a move towards a more segmented and rigorous care pathway, ensuring that novel treatments are matched with the most suitable patient phenotypes.

Key Market Players

• Pfizer Inc.
• GlaxoSmithKline plc.
• Boehringer Ingelheim GmbH.
• AstraZeneca PLC.
• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Novartis AG.
• Merck & Co. Inc.
• Vertex Pharmaceuticals Incorporated.
• Johnson & Johnson Consumer Inc.

Report Scope

In this report, the Global Cough Hypersensitivity Syndrome Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cough Hypersensitivity Syndrome Treatment Market, By Drug Class

• Antitussive Agents
• Inhaled Corticosteroids
• Short Acting Beta-2 Agonists
• Anti-Cholinergics
• Antihistamines
• Proton Pump Inhibitors
• Others

Cough Hypersensitivity Syndrome Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Cough Hypersensitivity Syndrome Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cough Hypersensitivity Syndrome Treatment Market.

Available Customizations:

Global Cough Hypersensitivity Syndrome Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cough Hypersensitivity Syndrome Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Antitussive Agents, Inhaled Corticosteroids, Short Acting Beta-2 Agonists, Anti-Cholinergics, Antihistamines, Proton Pump Inhibitors, Others)
  • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Cough Hypersensitivity Syndrome Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Canada Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Mexico Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Distribution Channel

7. Europe Cough Hypersensitivity Syndrome Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. France Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. United Kingdom Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. Italy Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. Spain Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. India Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. Japan Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Distribution Channel
  • 8.3.4. South Korea Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Distribution Channel
  • 8.3.5. Australia Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. UAE Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. South Africa Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Distribution Channel

10. South America Cough Hypersensitivity Syndrome Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Distribution Channel
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Colombia Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. Argentina Cough Hypersensitivity Syndrome Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cough Hypersensitivity Syndrome Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. GlaxoSmithKline plc.
• 15.3. Boehringer Ingelheim GmbH.
• 15.4. AstraZeneca PLC.
• 15.5. F. Hoffmann-La Roche Ltd.
• 15.6. Teva Pharmaceutical Industries Ltd.
• 15.7. Novartis AG.
• 15.8. Merck & Co. Inc.
• 15.9. Vertex Pharmaceuticals Incorporated.
• 15.10. Johnson & Johnson Consumer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer